Document is current
Any future updates will be listed below
-
Authors
Matza, Louis S. https://orcid.org/0000-0001-6374-5948
Li, Nan
Stewart, Katie D.
Hashim, Mahmoud
Denee, Tom
Pan, Feng
Zhang, Qiaoyi
Lee, Jennifer
Michaelides, Michel
Scholl, Hendrik P. N.
-
Funding
Funding for this research was provided by:
Janssen Pharmaceuticals (Janssen Pharmaceuticals)
- License Information
-
More Information
Article History
Received: 12 July 2024
Accepted: 21 January 2025
First Online: 17 March 2025
Declarations
:
: The coauthors certify that the study was performed in accordance with the ethical standards as described in the 1964 Declaration of Helsinki and its later amendments. Participants provided informed consent before starting interview procedures, and the study was approved by an independent institutional review board (Ethical & Independent Review Services; Study Number 22020-01).
: The coauthors employed by Janssen Pharmaceuticals contributed to the study design, health state development, interpretation of data, critical review of the manuscript, supervision, and decision to submit the manuscript for publication.
: NL, MH, TD, FP, QZ, and JL are employees of Janssen Pharmaceuticals. LM and KS are employed by Evidera, a company that received funding from Janssen Pharmaceuticals for time spent conducting this research. MM has received payment for consultation to Janssen Pharmaceuticals and MeiraGTx. MM was supported by the National Institute for Health and Care Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. HS is supported by the Swiss National Science Foundation (Project funding: “Developing novel outcomes for clinical trials in Stargardt disease using structure/function relationship and deep learning” #310030_201165), the Wellcome Trust (PINNACLE study), and the Foundation Fighting Blindness Clinical Research Institute (ProgStar study). HS is chief medical officer of Belite Bio and director of Bioptima AG. HS is a member of the Scientific Advisory Board of the following: Boehringer Ingelheim Pharma GmbH & Co, Janssen Research & Development, LLC (J&J Innovative Medicine), Kerna Ventures, Okuvision GmbH, and Tenpoint Therapeutics. HS is a member of the Investment Advisory Board of Droia NV. HS is a member of the Data Monitoring and Safety Board/Committee of ViGeneron (NCT06291935) and an adviser of the Steering Committee of Novo Nordisk (FOCUS trial; NCT03811561).
